Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TAFASITAMAB for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 6 adverse event reports in the FDA FAERS database where TAFASITAMAB was used for Neoplasm malignant.

Most Reported Side Effects for TAFASITAMAB

Side Effect Reports % Deaths Hosp.
Disease progression 470 33.8% 239 54
Diffuse large b-cell lymphoma 346 24.9% 206 37
Off label use 203 14.6% 43 73
Death 146 10.5% 146 18
Neutropenia 99 7.1% 19 45
Covid-19 96 6.9% 33 57
General physical health deterioration 75 5.4% 33 33
Pneumonia 66 4.7% 28 45
Febrile neutropenia 64 4.6% 7 55
Drug ineffective 62 4.5% 40 5
Thrombocytopenia 60 4.3% 13 20
Lymphoma 57 4.1% 7 3
Malignant neoplasm progression 47 3.4% 17 12
Infection 42 3.0% 8 14
Diarrhoea 39 2.8% 5 14

Other Indications for TAFASITAMAB

Diffuse large b-cell lymphoma (930) Follicular lymphoma (113) Product used for unknown indication (86) Diffuse large b-cell lymphoma refractory (40) Diffuse large b-cell lymphoma recurrent (37) Marginal zone lymphoma (24) Lymphoma (23) Non-hodgkin's lymphoma (22) B-cell lymphoma (18) High-grade b-cell lymphoma (17)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

TAFASITAMAB Full Profile All Neoplasm malignant Drugs TAFASITAMAB Demographics TAFASITAMAB Timeline